Altair Ventures Inc.

Altair Ventures Inc. is a junior gold explorer lead by a proven technical and finance team. Altair's flagship Kena project is located in British Columbia (Canada) and in a mining freindly jurisdiction with superb infrastructure. Kena is an advanced stage project with 16,5000 meters and 116 holes drilled to date and a NI 43-101 Compliant Mineral Resource Estimate with: total measured and indicated resources of 541,000 contained ounces of old and inferred resources totalling 557,000 ounces of gold. The project covers 7,609 hectacres and with over 8,000 meters of strike length, Kena is a large bulk tonnage deposit that is close to surface with tremendous potential for size. A drill program at Kena will commence in the Summer of 2012.

Altair Ventures Inc. trades on the TSX-Venture Exchange under the symbol "AVX".

biOasis Technologies Inc.

biOasis Technologies Inc. is a biopharmaceutical company focused on developing and commercializing proprietary pharmaceutical products and diagnostic technologies for central nervous system ("CNS") diseases and disorders. Of particular interest is the creation of therapeutic options for patient management to address the limitations to biodistribution presented by the properties of the blood-brain barrier ("BBB").

biOasis Technologies Inc. trades on the TSX-Venture Exchange under the symbol "BTI".

iCo Therapeutics

iCo Therapeutics Inc. is a reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications. iCo has exclusive worldwide rights to three products: iCo-007, in Phase 2 for the treatment of Diabetic Macular Edema (DME), iCo-008 (Bertilimumab), a product with Phase 2 clinical history to be developed for sight-threatening diseases; and an oral Amphotericin B delivery system for life-threatening infectious diseases. Immune Pharmaceuticals licensed systemic rights to iCo-008 in June 2011.

iCo Therapeutics trades on the TSX-Venture Exchange under the symbol "ICO".

Medallion Resources Ltd.

To solve the rare-earth supply shortage, Medallion is rethinking accepted rare-earth exploration and development strategies. Unlike present strategies, which focus on properties with complicated, expensive and untested metallurgy, Medallion is investigating a major source of rare earths---a source almost totally ignored by others. Led by veteran geologist and rare-earth expert Dr. Bill Bird, Medallion is examining the production of large, low-cost sources which can provide significant near-term production and long-term supplies of the rare earths. Dr. Bird and his superior technical team are challenging the status quo to meet the global supply shortage.

Medallion Resources Ltd. trades on the TSX-Venture Exchange under the symbol "MDL".

Medicago Inc.

Medicago is a clinical-stage biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs). Medicago's VLP manufacturing technology is based on a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has the potential to offer speed and cost advantages over competitive technologies. It can deliver a vaccine for testing in less than a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Medicago's VLPs resemble a virus, allowing them to be recognized readily by the immune system however they lack the core genetic material, making them non-infectious and unable to replicate.
The Company is using tobacco leaves to produce pandemic and seasonal influenza VLP vaccines for clinical testing. Medicago is also developing non-influenza vaccine candidates using this innovative plant-derived VLP platform.

Medicago Inc. trades on the TSX under the symbol "MDG".

Rokmaster Resources Corp.

Rokmaster Resources Corp. a junior gold exploration company with a simple focus: develop remarkable opportunities in mining friendly jurisdictions that provide superb infrastructure in North, Central and South America. Rokmaster is lead by a dynamic team with proven business acumen, an abundance of experience in exploration and mineral project development and proven economic production history. The company's lead project is the Pinaya Project located in Peru. Pinaya is a new acquisition and an exploration program will commence September 2012. The plan is to enhance and define existing multi-million ounce shallow, gold-rich oxide, shallow copper-gold porphyry and skarn deposits and explore for deeper super-giant sulphide porphyry targets. Past work by previous operators included over 46,000 meters of Diamond Drilling in 160 holes from 2004 to 2008, including the preparation of a National Instrument 43-101 compliant resource estimate for the Pinaya Project.

Rockmaster Resources Corp. trades on the TSX-Venture Exchange under the symbol "RKR".

Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer.

The Verisante Aura(tm) for skin cancer detection and the Verisante Core(tm) series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and the University of British Columbia and tested and refined on approximately 1,000 lesions at the Skin Care Centre at Vancouver General Hospital.

This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer immediate results for many of the most common cancers. Verisante is ISO 13485:2003 certified as a medical device manufacture

Verisante Technology, Inc. trades on the TSX-Venture Exchange under the symbol "VRS".